Hervorgehoben
JAHRESPARTNER
AKTUELLES
„Erfahrung kann man nicht überweisen“
Business Angels geben Start-ups mehr als Kapital: Zeit, Wissen und Begleitung in der kritischsten Phase. Warum sie die Wegbereiter des neuen Mittelstands sind –...
Precision oncology from the Rhineland
Cologne-based biotech start-up Disco Pharmaceuticals is taking a new approach to cancer therapy: using innovative cell-surface mapping to develop selective cancer therapeutics.
Malignant cells carry...
The Manufacturing Breakthrough for Personalised Cancer Therapies
Personalised cancer therapies have long been considered one of medicine’s most promising frontiers. Recent clinical results from Merck and Moderna involving mRNA-based approaches have...
Due diligence should meet the standards of the market it serves
Every early-stage life sciences asset is heading towards the most regulated industry in the world. The process used to evaluate these assets, however, is...
Navigating the increasing complexities of radiopharmaceutical therapy
The landscape for radiopharmaceutical therapies in oncology is evolving rapidly, propelled by early commercial successes and an expanding clinical pipeline. Yet realising the full...
Hivebuy: Haufe Group Ventures realisiert Exit
Frühphasen-Investor Haufe Group Ventures (CVC der Haufe Group) veräußert seine Beteiligung am Einkaufssoftware-Anbieter Hivebuy (Berlin) im Zuge der Übernahme durch die Conrad Electronic Gruppe....